Consistent with our proteomic findings, in relapsed myeloma patient tumor cells we found significant transcript decreases of CD53 and EVI2B, while MME (CD10) showed a significant increase (Fig. 3C). This evidence concerns the gene EVI2B and plasma cell myeloma.